Skip to content
10-Q

Quarterly Report

ABIOMED INC

0000950170-22-014795

← back to feed
Filed
Aug 4, 2022 12:00 AM ET
Period of report
—

On SEC.gov

Filing index ↗

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · Jul 29, 2022 45.46M sh
Shares Diluted Q1 2023 · Jun 30, 2022 45.92M sh
Shares Diluted Q1 2023 · Jun 30, 2021 45.31M sh
Stock Repurchased Q1 2023 · Jun 30, 2022 $14.52M
Stock Repurchased Q1 2023 · Jun 30, 2021 $0
Capex Q1 2023 · Jun 30, 2022 $6.78M
Capex Q1 2023 · Jun 30, 2021 $7.17M
Operating Cash Flow Q1 2023 · Jun 30, 2022 $68.1M
Operating Cash Flow Q1 2023 · Jun 30, 2021 $55.36M
Cash And Equivalents Q1 2023 · Jun 30, 2022 $180.49M
Cash And Equivalents Q1 2023 · Mar 31, 2022 $132.82M
Stockholders Equity Q1 2023 · Jun 30, 2022 $1.54B
Stockholders Equity Q1 2023 · Mar 31, 2022 $1.5B
Stockholders Equity Q1 2023 · Jun 30, 2021 $1.31B
Stockholders Equity Q1 2023 · Mar 31, 2021 $1.33B
Current Liabilities Q1 2023 · Jun 30, 2022 $140.76M
Current Liabilities Q1 2023 · Mar 31, 2022 $138.46M
Total Liabilities Q1 2023 · Jun 30, 2022 $167.44M
Total Liabilities Q1 2023 · Mar 31, 2022 $170.07M
Current Assets Q1 2023 · Jun 30, 2022 $1.06B
Current Assets Q1 2023 · Mar 31, 2022 $976.47M
Total Assets Q1 2023 · Jun 30, 2022 $1.7B
Total Assets Q1 2023 · Mar 31, 2022 $1.67B
Eps Diluted Q1 2023 · Jun 30, 2022 $1.19
Eps Diluted Q1 2023 · Jun 30, 2021 −$0.59
Eps Basic Q1 2023 · Jun 30, 2022 $1.20
Eps Basic Q1 2023 · Jun 30, 2021 −$0.59
Sga Expense Q1 2023 · Jun 30, 2022 $118M
Sga Expense Q1 2023 · Jun 30, 2021 $103.48M
Rd Expense Q1 2023 · Jun 30, 2022 $40.48M
Rd Expense Q1 2023 · Jun 30, 2021 $37.71M
Net Income Q1 2023 · Jun 30, 2022 $54.55M
Net Income Q1 2023 · Jun 30, 2021 −$26.53M
Operating Income Q1 2023 · Jun 30, 2022 $66.05M
Operating Income Q1 2023 · Jun 30, 2021 −$49.29M
Revenue Q1 2023 · Jun 30, 2022 $277.15M
Revenue Q1 2023 · Jun 30, 2021 $252.59M